News

Correspondence with Nature Reviews – "Tuberculosis – drugs in the 2016 development pipeline"


10 Mar 2017
by Working Group

WGND Co-chair, Barbara Laughon, and Sequella Inc. CEO, Carol Nacy, co-authored a correspondence to Nature Reviews regarding the October 2016 Article, “Tuberculosis”.

“In their recent Primer article (Tuberculosis. Nat. Rev. Dis. Primers 2, 16076 (2016))1, Madhukar Pai and colleagues give an important and comprehensive update on the advances made in  epidemiology, diagnosis, prevention and treatment for combatting the global tuberculosis (TB) epidemic. The Primer included the global TB drug pipeline (Figure 5) that represented the status of the field as of April 2016. However, several important new developments were reported at two major scientific conferences later in 2016: the EMBO Conference Tuberculosis 2016 in Paris, France, 19–23 September 2016 (http://www.tuberculosis2016.org), and the 47th Union World Congress on Lung Health and associated meetings in Liverpool, UK, 26–29 October 2016 (http://liverpool.worldlunghealth.org/). We believe that updates to the 2016 status of the TB drug pipeline would be of interest to readers of the journal…”

 

Continue reading here: http://www.nature.com/articles/nrdp201715

More News
9 Aug 2017
The United States Food and Drug Administration held a public workshop regarding scientific and clinical trial design considerations for development of new tuberculosis drug regimens. This public workshop was intended to provide information for and gain perspective pertaining to development efforts...
4 May 2017
Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today...
11 Apr 2017
Scientist at Rutgers University and their collaborators have published an article in Molecular Cell illustrating the three-dimensional structure of the drug target for the drug rifampicin. The abstract for the article is below. TITLE: Structural Basis of Mycobacterium tuberculosis Transcription and...